Theravance Biopharma Inc (TBPH) — Working Capital to Net Assets Ratio
Theravance Biopharma Inc (TBPH) has a Working Capital to Net Assets ratio of 128.1% as of December 2025. Working capital of $380.16 Million (current assets of $418.46 Million minus current liabilities of $38.30 Million) is measured against net assets of $296.72 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See TBPH cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Theravance Biopharma Inc Working Capital to Net Assets (2011–2025)
This chart shows how Theravance Biopharma Inc's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of December 2025, the ratio stands at 128.1%, reflecting working capital of $380.16 Million against net assets of $296.72 Million USD. For the complete balance sheet picture, see TBPH total assets.
Annual Working Capital to Net Assets for Theravance Biopharma Inc (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Theravance Biopharma Inc from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check TBPH cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 128.1% | $380.16 Million | $296.72 Million | $418.46 Million | $38.30 Million | ▲ +54.6 pp |
| 2024 | 73.5% | $128.98 Million | $175.54 Million | $161.07 Million | $32.09 Million | ▲ +22.4 pp |
| 2023 | 51.1% | $108.77 Million | $213.00 Million | $133.54 Million | $24.77 Million | ▼ -22.4 pp |
| 2022 | 73.5% | $324.75 Million | $441.80 Million | $353.46 Million | $28.71 Million | ▲ +130.0 pp |
| 2021 | -56.5% | $191.28 Million | $-338.57 Million | $249.87 Million | $58.59 Million | ▲ +32.3 pp |
| 2020 | -88.8% | $269.77 Million | $-303.75 Million | $393.34 Million | $123.57 Million | ▲ +12.5 pp |
| 2019 | -101.3% | $226.78 Million | $-223.84 Million | $338.49 Million | $111.70 Million | ▲ +740.5 pp |
| 2018 | -841.8% | $434.27 Million | $-51.59 Million | $532.82 Million | $98.55 Million | ▼ -1116.3 pp |
| 2017 | 274.5% | $316.20 Million | $115.18 Million | $378.75 Million | $62.55 Million | ▲ +137.7 pp |
| 2016 | 136.8% | $479.24 Million | $350.23 Million | $528.50 Million | $49.27 Million | ▲ +59.5 pp |
| 2015 | 77.3% | $188.00 Million | $243.06 Million | $237.47 Million | $49.47 Million | ▼ -21.2 pp |
| 2014 | 98.5% | $285.51 Million | $289.79 Million | $326.77 Million | $41.26 Million | ▼ -35.0 pp |
| 2013 | 133.5% | $-22.75 Million | $-17.04 Million | $14.11 Million | $36.85 Million | ▼ -558.7 pp |
| 2012 | 692.2% | $-11.84 Million | $-1.71 Million | $10.84 Million | $22.67 Million | ▲ +668.4 pp |
| 2011 | 23.9% | $-33.56 Million | $-140.72 Million | $2.32 Million | $35.88 Million | — |